Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation

D. Li, J. Liu, B. Guo, C. Liang, L. Dang, C. Lu, X. He, H.Y.S. Cheung, L. Xu, B. He, B. Liu, A.B. Shaikh, F. Li, L. Wang, Z. Yang, D.W.T. Au, S. Peng, Z. Zhang, B.T. Zhang, X. PanA. Qian, P. Shang, L. Xiao, B. Jiang, C.K.C. Wong, Jiake Xu, Z. Bian, Z. Liang, D.A. Guo, H. Zhu, W. Tan, A. Lu, G. Zhang

Research output: Contribution to journalArticlepeer-review

397 Citations (Scopus)


Emerging evidence indicates that osteoclasts direct osteoblastic bone formation. MicroRNAs (miRNAs) have a crucial role in regulating osteoclast and osteoblast function. However, whether miRNAs mediate osteoclast-directed osteoblastic bone formation is mostly unknown. Here, we show that increased osteoclastic miR-214-3p associates with both elevated serum exosomal miR-214-3p and reduced bone formation in elderly women with fractures and in ovariectomized (OVX) mice. Osteoclast-specific miR-214-3p knock-in mice have elevated serum exosomal miR-214-3p and reduced bone formation that is rescued by osteoclast-targeted antagomir-214-3p treatment. We further demonstrate that osteoclast-derived exosomal miR-214-3p is transferred to osteoblasts to inhibit osteoblast activity in vitro and reduce bone formation in vivo. Moreover, osteoclast-targeted miR-214-3p inhibition promotes bone formation in ageing OVX mice. Collectively, our results suggest that osteoclast-derived exosomal miR-214-3p transfers to osteoblasts to inhibit bone formation. Inhibition of miR-214-3p in osteoclasts may be a strategy for treating skeletal disorders involving a reduction in bone formation.
Original languageEnglish
Article number10872
JournalNature Communications
Publication statusPublished - 7 Mar 2016


Dive into the research topics of 'Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation'. Together they form a unique fingerprint.

Cite this